Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Reactogenicity and Immunogenicity of Vaginal ZM96gp140
This study has been terminated.
Sponsors and Collaborators: St George's, University of London
Bill and Melinda Gates Foundation
York Hospitals
Information provided by: St George's, University of London
ClinicalTrials.gov Identifier: NCT00637962
  Purpose

To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with ZM96gp140 glycoprotein administered 9 times over a 3 week period.


Condition Intervention Phase
HIV Infections
Human Immunodeficiency Virus
Acquired Immune Deficiency Syndrome
Biological: HIV glycoprotein 140 ZM96 (vaccine)
Biological: Carbopol 974
Phase I

MedlinePlus related topics: AIDS
Drug Information available for: Krestin Ethanol
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety Study
Official Title: Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Nine Vaginal Immunisations With HIV ZM96gp140 Glycoprotein

Further study details as provided by St George's, University of London:

Primary Outcome Measures:
  • To determine the local and systemic safety of vaginal immunisation with ZM96gp140 glycoprotein administered 9 times over a 3 week period. [ Time Frame: 13 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • frequency of subjects mounting a cervico-vaginal IgA and IgG response to gp140 after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]
  • frequency of subjects mounting a serum IgG and IgA response to gp140 after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]
  • frequency of subjects with a T-cell response to gp140 in blood after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]
  • frequency of cellular responses to gp140 in cervical cells after a cycle of 9 vaginal immunisations [ Time Frame: 13 wks ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: September 2007
Estimated Study Completion Date: January 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
gp140ZM96 + gel
Biological: HIV glycoprotein 140 ZM96 (vaccine)
vaginal immunisation with 100ug gp140ZM96 antigen in gel on 9 occasions in one menstrual cycle
2: Placebo Comparator
gel alone
Biological: Carbopol 974
vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • They are adult female volunteers, 18 to 45 years of age, who have signed an informed consent form following a detailed written explanation of participation in the protocol.
  • They are volunteers who are in good health as determined by medical history, physical examination and clinical judgement.
  • They are available for the duration of the study.
  • They are women who, if capable of becoming pregnant during the study, have agreed to have a pregnancy test immediately before immunisation, and to use appropriate contraception methods during the whole study period. Appropriate contraception shall include physician-prescribed oral hormonal agents, barrier contraceptives, regular and consistent use of condoms without spermicidal agents, or intrauterine devices only. Progesterone-only contraceptives are not suitable due to the lack of a regular menstrual cycle.
  • They have agreed not to undertake any vaginal practices other than receptive intercourse with a male or use of sanitary tampons during menses. Use of condoms without spermicidal agents is encouraged.
  • They have not donated blood during 3 months prior to study entry and agree to not donate for 3 months after the end of their participation in the study.

Exclusion Criteria:

  • They have hypersensitivity to any component of the vaccine used in this study.
  • They are found to be HIV antibody or HIV proviral DNA positive at the time of initial screening.
  • They have a known or suspected history of cervico-vaginal disease, malignancy or abnormality discovered at time of screening.
  • They present in the samples obtained at the screening visit:

    • a clinically significant amount of protein or haemoglobin in the urine sample, determined by urine dipstick.
    • a clinically significant abnormality in the haematological or biochemical assays.
    • Positive tests for Hepatitis B and/or C infection An abnormal value will be defined by the ranges quoted by The Doctors Laboratory for the Vaccine Institute site and Pathology Department, York Hospital for the York site.
  • They have a known or suspected impairment of lung, heart, liver, kidney, diseases, blood disorders or immune dysfunction.
  • They are receiving immunosuppressive therapy (including systemic steroids).
  • They are receiving any medications via vaginal route.
  • They have any acute infections (including fever greater than or equal to 38°C) or any chronic disease.
  • They present a current problem with substance abuse or with a history of substance abuse which, in the opinion of the investigator, might interfere with participation in the study.
  • They have any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  • They have received an investigational agent within 3 months prior to study entry.
  • They cannot speak fluent English, or are planning to leave the area of the study site prior to the end of the study period, or are likely not to complete the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00637962

Locations
United Kingdom, England
St George's Vaccine Institute
London, England, United Kingdom, SW17 0RE
York Hospital
York, England, United Kingdom, YO31 7WA
Sponsors and Collaborators
St George's, University of London
Bill and Melinda Gates Foundation
York Hospitals
Investigators
Principal Investigator: David JM Lewis, MD St George's, University of London, UK
Principal Investigator: Charles Lacey, MD York Hospitals
Study Director: David JM Lewis, MD St George's, University of London, UK
  More Information

St George's Vaccine Institute Homepage  This link exits the ClinicalTrials.gov site

Responsible Party: St George's University of London ( Dr David JM Lewis, Chief Investigator )
Study ID Numbers: 2007-000781-20, 07/Q0803/29, SG06RS02
Study First Received: March 11, 2008
Last Updated: December 16, 2008
ClinicalTrials.gov Identifier: NCT00637962  
Health Authority: United Kingdom: Research Ethics Committee;   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by St George's, University of London:
HIV
AIDS
Vaccine
intravaginal
mucosal
HIV Seronegativity

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Interferons
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Healthy
PS-K
Retroviridae Infections
Immunologic Deficiency Syndromes
Ethanol

Additional relevant MeSH terms:
Interferon Inducers
Anti-Infective Agents
Radiation-Protective Agents
RNA Virus Infections
Slow Virus Diseases
Disease
Immune System Diseases
Immunologic Factors
Antineoplastic Agents
Physiological Effects of Drugs
Adjuvants, Immunologic
Infection
Antibiotics, Antineoplastic
Protective Agents
Antiviral Agents
Pharmacologic Actions
Pathologic Processes
Therapeutic Uses
Syndrome
Lentivirus Infections

ClinicalTrials.gov processed this record on January 16, 2009